Nanocarrier for poorly water-soluble anticancer drugs - Barriers of translation and solutions

AAPS PharmSciTech

Volumn 15, Issue 4, 2014, Pages 822-833

  Narvekar, Mayuri ^a   Xue, Hui Yi ^a   Eoh, June Young ^a   Wong, Ho Lun ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

anti cancer drug; drug delivery; nanocarrier; poorly water soluble drugs; translation

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; DENDRIMER; LIPOSOME; NANOCARRIER; NANOMATERIAL; NANOSTRUCTURED LIPID CARRIER; PHOSPHOLIPID; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; LIPID; NANOPARTICLE; POLYMER; SOLUTION AND SOLUBILITY; WATER;

DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; LIPOSOMAL DELIVERY; MICELLE; MISCIBILITY; NANOENCAPSULATION; NANOTECHNOLOGY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SCALE UP; ANIMAL; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; POLYMERS; SOLUBILITY; SOLUTIONS; WATER;

EID: 84905126089     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0107-x     Document Type: Review

References (98)

1. Ramaswami R, Harding V, Newsom-Davis T. Novel cancer therapies: treatments driven by tumour biology. Postgrad Med J. 2013;89(1057):652-8.
2. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284:109-22.
3. Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB. Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci. 2013;34(9):508-17.
4. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56(9):1273-89. (Pubitemid 38510474)
5. Ku MS. Use of the biopharmaceutical classification system in early drug development. AAPS J. 2008;10(1):208-12.
6. Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs. J Med Chem. 2004;47:2393-404.
7. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-98. (Pubitemid 32778603)
8. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727. doi:10.5402/2012/195727.
9. Shin HC, Alani AWG, Rao DA, Rockich NC, Kwon GS. Multidrug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release. 2009;140:294-300.
10. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharmaceut Bull. 2001;49:1444-47. (Pubitemid 33043274)
11. Ma Y, Zheng Y, Zeng X, Jiang L, Chen H, Liu R, et al. Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment. Int J Nanomedicine. 2011;6:2679-88.
12. Drug.com. Paclitaxel injection, USP, monograph. .http://www.drugs.com/ pro/paclitaxel.html (2013). Accessed 29 Oct 2013.
13. Muthu MS, Kulkarni SA, Raju A, Feng SS. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials. 2012;33:3494-501.
14. Mohammed AR, Weston N, Coombes AGA, Fitzgerald M, Perrie Y. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability. Int J Pharm. 2004;285:23-34. (Pubitemid 39361533)
15. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, et al. Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005;59:177-87. (Pubitemid 39573451)
16. Harfouche R, Basu S, Soni S, Hentschel DM, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of phos-phatidylinositol- 3-kinase signaling inhibits angiogenesis. Angiogenesis. 2009;12:325-38.
17. Sistla A, Smith DJ, Kobrinsky NL, Kumar K. Pharmacokinetics and tissue distribution of liposomal etoposide in rats. Drug Deliv. 2009;16(8):423-9.
18. Jinturkar KA, Anish C, Kumar MK, Bagchi T, Panda AK, Misra AR. Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials. 2012;33(8):2492-507.
19. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-77. (Pubitemid 30326695)
20. Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. Preparation and characteristics of nanostructured lipid carriers for controlreleasing progesterone by melt-emulsification. Colloids Surf B: Biointerfaces. 2007;60:174-9. (Pubitemid 350030429)
21. Saupe A, Rades T. Solid lipid nanoparticles. Nanocarrier technologies. Springer; 2007. p. 41-50.
22. Wong HL, Bendayan R, Rauth AM, Li Y,Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59:491-504. (Pubitemid 47259227)
23. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14:458-62. (Pubitemid 27205004)
24. Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 2006;23:1574-85. (Pubitemid 43993820)
25. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751-7. (Pubitemid 29227107)
26. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm. 2008;348:137-45. (Pubitemid 350266242)
27. Lim SJ, Lee MK, Kim CK. Altered chemical and biological activities of all-trans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release. 2004;100:53-61.
28. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007;59:522-30. (Pubitemid 47271894)
29. Müller RH, RadtkeM,Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131-55. (Pubitemid 35379959)
30. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26:523-80.
31. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71:161-72.
32. Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B: Biointerfaces. 2011;85:262-9.
33. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int JPharma. 2008;361:239-44.
34. Chinsriwongkul A, Chareanputtakhun P, Ngawhirunpat T, Rojanarata T, Sila-on W, Ruktanonchai U, et al. Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug. AAPS PharmSciTech. 2012;13:150-8.
35. Fang M, Jin Y, Bao W, Gao H, Xu M, Wang D, et al. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int J Nanomed. 2012;7:5395-404.
36. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B: Biointerfaces. 2010;81:263-73.
37. Liu X, Wang Z, Feng R, Hu Y, Huang G. A novel approach for systematic delivery of a hydrophobic anti-leukemia agent tamibarotene mediated by nanostructured lipid carrier. J Biomed Nanotech. 2013;9:1586-93.
38. Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev. 2004;56:1243-55. (Pubitemid 38510472)
39. Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334:157-75.
40. Li X, Du L, Wang C, Liu Y, Mei X, Jin Y. Highly efficient and lowly toxic docetaxel nanoemulsions for intravenous injection to animals. Die Pharmazie. 2011;66:479-83.
41. Gao H, Pang Z, Pan S, Cao S, Yang Z, Chen C, et al . Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharmacal Res. 2012;35:333-41.
42. Ahmed K, Li Y, McClements DJ, Xiao H. Nanoemulsion-and emulsion-based delivery systems for curcumin: encapsulation and release properties. Food Chem. 2012;132:799-807.
43. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharmaceut. 2009;6:928-39.
44. Chinsriwongkul A, Opanasopit P, Ngawhirunpat T, Rojanarata T, Sila-On W, Ruktanonchai U. Oleic acid enhances all-trans retinoic acid loading in nano-lipid emulsions. PDA J Pharm Sci Technol. 2010;64:113-23.
45. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, et al.Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol. 2009;63(6):1049-63.
46. FDANews EZline. Phase III trial of tocosol paclitaxel does not meet primary endpoint http://fdanews.com/newsletter/article?issueId= 10769&articleId=98911 (2007). Accessed 28 Oct 2013.
47. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):701-5.
48. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30:1627-34.
49. Narvekar M, Xue HY, Wong HL. A novel hybrid delivery system: polymer-oil nanostructured carrier for controlled delivery of highly lipophilic drug all-trans-retinoic acid (ATRA). Int J Pharm. 2012;436:721-31.
50. Xue HY, Wong HL. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano. 2011;5:7034-47.
51. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2:1696-702.
52. Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Exp Opin Drug Deliv. 2010;7:145-58.
53. Matsumura Y, Kataoka K. Preclinical and clinical studies of anti-cancer agent-incorporating polymer micelles. Cancer Sci. 2009;100:572-9.
54. Lukyanov A, Gao Z, Mazzola L, Torchilin V. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharma Res. 2002;19:1424-29. (Pubitemid 35266545)
55. Zhu C, Jung S, Luo S, Meng F, Zhu X, Park TG, et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials. 2010;31:2408-16.
56. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, et al . NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92:1240-46. (Pubitemid 40604398)
57. Lim WT, Tan EH, Toh CK, Hee SW, Leong SS, Ang PCS, et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors. Ann Oncol. 2010;21:382-8.
58. Mu CF, Balakrishnan P, Cui FD, Yin YM, Lee YB, Choi HG, et al . The effects of mixed MPEG-PLA/Pluronic® copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials. 2010;31:2371-79.
59. Zhang Y, Wang X, Wang J, Zhang X, Zhang Q. Octreotidemodified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells. Pharmaceutical research. 2011;28:1167-78.
60. Kawano K, Watanabe M, Yamamoto T, Yokoyama M, Opanasopit P, Okano T, et al. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release. 2006;112:329-32.
61. Clinicaltrials.gov. A Phase III study of NK105 in patients with breast cancer. http://clinicaltrials.gov/show/NCT01644890 (2012). Accessed 28 Oct 2013.
62. Clinicaltrials.gov. Evaluate the efficacy and safety of Genexol®-PM compared to Genexol® in recurrent ormetastatic breast cancer. http://clinicaltrials.gov/ct2/show/NCT00876486?term=Genexol&rank=1 (2012). Accessed 28 Oct 2013.
63. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine. 2008;4:273-82.
64. Khandare JJ, Jayant S, Singh A, Chandna P, Wang Y, Vorsa N, et al. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug Chem. 2006;17:1464-72. (Pubitemid 44851491)
65. McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS. 2011;25(8):1057-64.
66. Morgan MT, Nakanishi Y, Kroll DJ, Griset AP, Carnahan MA, WathierM, et al.Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res. 2006;66:11913-21. (Pubitemid 46094204)
67. Gajbhiye V, Jain NK. The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials. 2011;32(26):6213-25.
68. Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, et al. Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv. 2013;2013:905091.
69. Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170(3):365-72.
70. Yuan Y, Zhao Y, Xin S, Wu N, Wen J, Li S, et al. A novel PEGylated liposome-encapsulated SANT75 suppresses tumor growth through inhibiting hedgehog signaling pathway. PLoS ONE. 2013;8(4):e60266.
71. Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Ther. 2012;11(1):165-73.
72. Apiratikul N, Penglong T, Suksen K, Svasti S, Chairoungdua A, Yingyongnarongkul B. In vitro delivery of curcumin with cholesterol-based cationic liposomes. Russian J Bioorgan Chem. 2013;39:444-50.
73. Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. Apoptosis-induced anticancer effect of transferrin-conjugated solid lipid nanoparticles of curcumin. Cancer Nanotech. 2012;3:65-81.
74. Fang M, Jin Y, Bao W, Gao H, Xu M, Wang D, et al. In vitro characterization and in vivo evaluation of nanostructured lipid curcumin carriers for intragastric administration. Int J Nanomedicine. 2012;7:5395-404.
75. Ahmed K, Li Y, McClements DJ, Xiao H. Nanoemulsionand emulsion-based delivery systems for curcumin: encapsulation and release properties. Food Chem. 2012;132:799-807.
76. Cho H, Lai TC, Kwon GS. Poly(ethylene glycol)-blockpoly(- caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer. J Control Release. 2013;166(1):1-9.
77. Hasenstein JR, Shin HC, Kasmerchak K, Buehler D, Kwon GS, Kozak KR. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing paclitaxel, rapamycin, and 17-AAG. Mol Cancer Ther. 2012;11(10):2233-42.
78. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505-22.
79. Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci. 1996;85:530-36. (Pubitemid 26153217)
80. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci. 2004;93:1804-14. (Pubitemid 38823706)
81. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73:121-36. (Pubitemid 32539245)
82. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release. 2002;79:123-35. (Pubitemid 34164166)
83. Maherani B, Arab-Tehrany ER, Mozafari M, Gaiani C, Linder M. Liposomes: a review of manufacturing techniques and targeting strategies. Curr Nanoscience. 2011;7:436-52.
84. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615-27.
85. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5:496-504.
86. Pisanic 2nd TR, Blackwell JD, Shubayev VI, Fiñones RR, Jin S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials. 2007;28:2572-81. (Pubitemid 46367215)
87. Fischer HC, Chan WCW. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol. 2007;18:565-71.
88. Budhian A, Siegel SJ, Winey KI. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencap. 2005;22:773-85. (Pubitemid 43158197)
89. Yang Z, Luo X, Zhang X, Liu J, Jiang Q. Targeted delivery of 10-hydroxycamptothecin to human breast cancers by cyclic RGDmodified lipid-polymer hybrid nanoparticles. Biomed Mater. 2013;8:025012.
90. Mora-Barrantes I, Valentín JL, Rodríguez A, Quijada-Garrido I, Paris R. Poly (styrene)/silica hybrid nanoparticles prepared via ATRP as high-quality fillers in elastomeric composites. J Mater Chem. 2012;22:1403-10.
91. Tchoul MN, Dalton M, Tan LS, Dong H, Hui CM, Matyjaszewski K, et al. Enhancing the fraction of grafted polystyrene on silica hybrid nanoparticles. Polymer. 2012;53:79-86.
92. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60:1615-26.
93. Han H, Davis ME. Single antibody, targeted nanoparticle delivery of camptothecin. Mol Pharm. 2013;10:2558-67.
94. Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F. Benefit of anti-HER2-coated paclitaxel-loaded immunonanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release. 2010;144:324-31.
95. Pan J, Feng SS. Targeted delivery of paclitaxel using folatedecorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials. 2008;29:2663-72.
96. Danhier F, Feron O, Préat V. To exploit the tumor micro-environment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148:135-46.
97. Shimada T, Ueda M, Jinno H, Chiba N, Wada M, Watanabe J, et al . Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res. 2009;29(4):1009-14.
98. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev. 2007;59:164-82. (Pubitemid 46773052)